News about 'janssen'

Scientists at Janssen Pharmaceutica have characterized a novel resistance mechanism to Bedaquiline (BDQ), a second line antibiotic for the treatment of MDR-TB. The research study , published in Plos One , showed that tuberculosis resisted BDQ treatment by developing a mechanism to pump the drug out...

The European Medicines Agency (EMA) has recently approved Sirturo (bedaquiline) for conditional use in the European Union for adults suffering from pulmonary MDR-TB. The press release from Multimedia News Release can be found at: http://www.multivu.com/mnr/65014-sirturo-treatment-multi-drug-...

From the Stop TB Parntership News: The World Health Organization (WHO) has issued interim guidance on the use of bedaquiline, a new tuberculosis drug, for the treatment of multidrug-resistant tuberculosis (MDR-TB). Bedaquiline was granted accelerated approval by the United States Food and Drug...

Press Release from FDA can be found at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm . Press Release from Janssen is below. FDA Grants Accelerated Approval for SIRTURO™ (bedaquiline) as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant...

Yesterday, Nov. 28th, the FDA Ant-infective Drug Advisory Committee voted to recommend Janssen ‘s Bedaquiline for accelerated approval for the treatment of MDR tuberculosis. You can access materials from the meeting at http://www.fda.gov/AdvisoryCommittees/Calendar/ucm321011.htm . The sponsor and...

Structure of Bedaquiline This week it was announced the Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for their drug Bedaquiline (a.k.a. TMC-207). For additional information on...